Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Sézary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-beta on the cell surface.

Chung JS, Shiue LH, Duvic M, Pandya A, Cruz PD Jr, Ariizumi K.

Blood. 2011 Mar 24;117(12):3382-90. doi: 10.1182/blood-2010-08-302034. Epub 2011 Jan 20.

2.

Syndecan-4 mediates the coinhibitory function of DC-HIL on T cell activation.

Chung JS, Dougherty I, Cruz PD Jr, Ariizumi K.

J Immunol. 2007 Nov 1;179(9):5778-84.

3.

The DC-HIL/syndecan-4 pathway inhibits human allogeneic T-cell responses.

Chung JS, Bonkobara M, Tomihari M, Cruz PD Jr, Ariizumi K.

Eur J Immunol. 2009 Apr;39(4):965-74. doi: 10.1002/eji.200838990.

4.

Depleting syndecan-4+ T lymphocytes using toxin-bearing dendritic cell-associated heparan sulfate proteoglycan-dependent integrin ligand: a new opportunity for treating activated T cell-driven disease.

Akiyoshi H, Chung JS, Tomihari M, Cruz PD Jr, Ariizumi K.

J Immunol. 2010 Apr 1;184(7):3554-61. doi: 10.4049/jimmunol.0903250. Epub 2010 Feb 22.

5.

The DC-HIL/syndecan-4 pathway regulates autoimmune responses through myeloid-derived suppressor cells.

Chung JS, Tamura K, Akiyoshi H, Cruz PD Jr, Ariizumi K.

J Immunol. 2014 Mar 15;192(6):2576-84. doi: 10.4049/jimmunol.1301857. Epub 2014 Feb 10.

6.

Binding of DC-HIL to dermatophytic fungi induces tyrosine phosphorylation and potentiates antigen presenting cell function.

Chung JS, Yudate T, Tomihari M, Akiyoshi H, Cruz PD Jr, Ariizumi K.

J Immunol. 2009 Oct 15;183(8):5190-8. doi: 10.4049/jimmunol.0901319. Epub 2009 Sep 30.

7.

Engagement of ILT2/CD85j in Sézary syndrome cells inhibits their CD3/TCR signaling.

Nikolova M, Musette P, Bagot M, Boumsell L, Bensussan A.

Blood. 2002 Aug 1;100(3):1019-25.

8.

DC-HIL is a negative regulator of T lymphocyte activation.

Chung JS, Sato K, Dougherty II, Cruz PD Jr, Ariizumi K.

Blood. 2007 May 15;109(10):4320-7. Epub 2007 Feb 6.

9.

Inhibition of T-cell activation by syndecan-4 is mediated by CD148 through protein tyrosine phosphatase activity.

Chung JS, Cruz PD Jr, Ariizumi K.

Eur J Immunol. 2011 Jun;41(6):1794-9. doi: 10.1002/eji.201041233. Epub 2011 May 9.

10.

DC-HIL/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumor-reactive T cells.

Tomihari M, Chung JS, Akiyoshi H, Cruz PD Jr, Ariizumi K.

Cancer Res. 2010 Jul 15;70(14):5778-87. doi: 10.1158/0008-5472.CAN-09-2538. Epub 2010 Jun 22.

11.

Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells.

Zhang C, Li B, Gaikwad AS, Haridas V, Xu Z, Gutterman JU, Duvic M.

J Invest Dermatol. 2008 Nov;128(11):2728-35. doi: 10.1038/jid.2008.138. Epub 2008 May 22.

12.

Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells.

Berger CL, Tigelaar R, Cohen J, Mariwalla K, Trinh J, Wang N, Edelson RL.

Blood. 2005 Feb 15;105(4):1640-7. Epub 2004 Oct 28.

14.

Loss of receptors for transforming growth factor beta in human T-cell malignancies.

Kadin ME, Cavaille-Coll MW, Gertz R, Massagué J, Cheifetz S, George D.

Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6002-6.

15.

High numbers of DC-SIGN+ dendritic cells in lesional skin of cutaneous T-cell lymphoma.

Schlapbach C, Ochsenbein A, Kaelin U, Hassan AS, Hunger RE, Yawalkar N.

J Am Acad Dermatol. 2010 Jun;62(6):995-1004. doi: 10.1016/j.jaad.2009.06.082.

PMID:
20466174
16.

Identification of cell surface molecules characterizing human cutaneous T-cell lymphomas.

Nikolova M, Bagot M, Boumsell L, Bensussan A.

Leuk Lymphoma. 2002 Apr;43(4):741-6. Review.

PMID:
12153159
17.

Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.

Poenitz N, Simon-Ackermann J, Gratchev A, Qadoumi M, Klemke CD, Stadler R, Kremer A, Radenhausen M, Henke U, Assaf C, Utikal J, Goerdt S, Dippel E.

Dermatology. 2005;211(2):84-92.

PMID:
16088151
18.

DC-HIL-expressing myelomonocytic cells are critical promoters of melanoma growth.

Chung JS, Tamura K, Cruz PD Jr, Ariizumi K.

J Invest Dermatol. 2014 Nov;134(11):2784-94. doi: 10.1038/jid.2014.254. Epub 2014 Jun 17.

19.

The DC-HIL ligand syndecan-4 is a negative regulator of T-cell allo-reactivity responsible for graft-versus-host disease.

Chung JS, Tomihari M, Tamura K, Kojima T, Cruz PD Jr, Ariizumi K.

Immunology. 2013 Feb;138(2):173-82. doi: 10.1111/imm.12027.

20.

Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.

Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C.

J Am Acad Dermatol. 2014 Feb;70(2):205.e1-16; quiz 221-2. doi: 10.1016/j.jaad.2013.07.049. Review.

PMID:
24438969

Supplemental Content

Support Center